194 related articles for article (PubMed ID: 16699034)
21. Herpes simplex virus targeting to the EGF receptor by a gD-specific soluble bridging molecule.
Nakano K; Asano R; Tsumoto K; Kwon H; Goins WF; Kumagai I; Cohen JB; Glorioso JC
Mol Ther; 2005 Apr; 11(4):617-26. PubMed ID: 15771964
[TBL] [Abstract][Full Text] [Related]
22. Glycoprotein D homologs in herpes simplex virus type 1, pseudorabies virus, and bovine herpes virus type 1 bind directly to human HveC(nectin-1) with different affinities.
Connolly SA; Whitbeck JJ; Rux AH; Krummenacher C; van Drunen Littel-van den Hurk S; Cohen GH; Eisenberg RJ
Virology; 2001 Feb; 280(1):7-18. PubMed ID: 11162814
[TBL] [Abstract][Full Text] [Related]
23. Mutations in the N termini of herpes simplex virus type 1 and 2 gDs alter functional interactions with the entry/fusion receptors HVEM, nectin-2, and 3-O-sulfated heparan sulfate but not with nectin-1.
Yoon M; Zago A; Shukla D; Spear PG
J Virol; 2003 Sep; 77(17):9221-31. PubMed ID: 12915538
[TBL] [Abstract][Full Text] [Related]
24. HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses.
Menotti L; Avitabile E; Gatta V; Malatesta P; Petrovic B; Campadelli-Fiume G
Viruses; 2018 Jun; 10(7):. PubMed ID: 29966356
[TBL] [Abstract][Full Text] [Related]
25. Effects of linker-insertion mutations in herpes simplex virus 1 gD on glycoprotein-induced fusion with cells expressing HVEM or nectin-1.
Jogger CR; Montgomery RI; Spear PG
Virology; 2004 Jan; 318(1):318-26. PubMed ID: 14972557
[TBL] [Abstract][Full Text] [Related]
26. Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry.
Whitbeck JC; Peng C; Lou H; Xu R; Willis SH; Ponce de Leon M; Peng T; Nicola AV; Montgomery RI; Warner MS; Soulika AM; Spruce LA; Moore WT; Lambris JD; Spear PG; Cohen GH; Eisenberg RJ
J Virol; 1997 Aug; 71(8):6083-93. PubMed ID: 9223502
[TBL] [Abstract][Full Text] [Related]
27. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257
[TBL] [Abstract][Full Text] [Related]
28. Comparison of murine and human nectin1 binding to herpes simplex virus glycoprotein D (gD) reveals a weak interaction of murine nectin1 to gD and a gD-dependent pathway of entry.
Menotti L; Avitabile E; Dubreuil P; Lopez M; Campadelli-Fiume G
Virology; 2001 Apr; 282(2):256-66. PubMed ID: 11289808
[TBL] [Abstract][Full Text] [Related]
29. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging.
Daldrup-Link HE; Meier R; Rudelius M; Piontek G; Piert M; Metz S; Settles M; Uherek C; Wels W; Schlegel J; Rummeny EJ
Eur Radiol; 2005 Jan; 15(1):4-13. PubMed ID: 15616814
[TBL] [Abstract][Full Text] [Related]
30. Retargeting Strategies for Oncolytic Herpes Simplex Viruses.
Campadelli-Fiume G; Petrovic B; Leoni V; Gianni T; Avitabile E; Casiraghi C; Gatta V
Viruses; 2016 Feb; 8(3):63. PubMed ID: 26927159
[TBL] [Abstract][Full Text] [Related]
31. The soluble ectodomain of herpes simplex virus gD contains a membrane-proximal pro-fusion domain and suffices to mediate virus entry.
Cocchi F; Fusco D; Menotti L; Gianni T; Eisenberg RJ; Cohen GH; Campadelli-Fiume G
Proc Natl Acad Sci U S A; 2004 May; 101(19):7445-50. PubMed ID: 15123804
[TBL] [Abstract][Full Text] [Related]
32. Decreased survival of human breast cancer cells expressing HER2/neu on in vitro incubation with an anti-HER2/neu antibody fused to C5a or C5a desArg.
Fuenmayor J; Perez-Vazquez K; Perez-Witzke D; Penichet ML; Montano RF
Mol Cancer Ther; 2010 Aug; 9(8):2175-85. PubMed ID: 20682652
[TBL] [Abstract][Full Text] [Related]
33. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
34. Substitution in the murine nectin1 receptor of a single conserved amino acid at a position distal from the herpes simplex virus gD binding site confers high-affinity binding to gD.
Menotti L; Casadio R; Bertucci C; Lopez M; Campadelli-Fiume G
J Virol; 2002 Jun; 76(11):5463-71. PubMed ID: 11991974
[TBL] [Abstract][Full Text] [Related]
35. A Functional Interaction between Herpes Simplex Virus 1 Glycoprotein gH/gL Domains I and II and gD Is Defined by Using Alphaherpesvirus gH and gL Chimeras.
Fan Q; Longnecker R; Connolly SA
J Virol; 2015 Jul; 89(14):7159-69. PubMed ID: 25926636
[TBL] [Abstract][Full Text] [Related]
36. {alpha}V{beta}3-integrin routes herpes simplex virus to an entry pathway dependent on cholesterol-rich lipid rafts and dynamin2.
Gianni T; Gatta V; Campadelli-Fiume G
Proc Natl Acad Sci U S A; 2010 Dec; 107(51):22260-5. PubMed ID: 21135248
[TBL] [Abstract][Full Text] [Related]
37. Localization of the gD-binding region of the human herpes simplex virus receptor, HveA.
Whitbeck JC; Connolly SA; Willis SH; Hou W; Krummenacher C; Ponce de Leon M; Lou H; Baribaud I; Eisenberg RJ; Cohen GH
J Virol; 2001 Jan; 75(1):171-80. PubMed ID: 11119586
[TBL] [Abstract][Full Text] [Related]
38. Interaction between herpesvirus entry mediator and HSV-2 glycoproteins mediates HIV-1 entry of HSV-2-infected epithelial cells.
Hu K; He S; Xiao J; Li M; Luo S; Zhang M; Hu Q
J Gen Virol; 2017 Sep; 98(9):2351-2361. PubMed ID: 28809154
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.
Menotti L; Nicoletti G; Gatta V; Croci S; Landuzzi L; De Giovanni C; Nanni P; Lollini PL; Campadelli-Fiume G
Proc Natl Acad Sci U S A; 2009 Jun; 106(22):9039-44. PubMed ID: 19458262
[TBL] [Abstract][Full Text] [Related]
40. Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.
Ding H; Helguera G; Rodríguez JA; Markman J; Luria-Pérez R; Gangalum P; Portilla-Arias J; Inoue S; Daniels-Wells TR; Black K; Holler E; Penichet ML; Ljubimova JY
J Control Release; 2013 Nov; 171(3):322-9. PubMed ID: 23770212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
